Group 1 - The sixth meeting of the fourth supervisory board of Shaoxing Baisimei Chemical Co., Ltd. was held on August 18, 2025, with all six supervisors present, confirming compliance with legal and regulatory requirements [1] - The supervisory board approved the 2025 semi-annual report, stating that it accurately reflects the company's actual situation without any false records or misleading statements [1][2] - The company strictly adhered to relevant regulations regarding the storage and use of raised funds, with all procedures followed correctly, and no violations reported [2] Group 2 - The company decided to postpone some fundraising investment projects based on the usage progress of raised funds and actual operating conditions, ensuring no change in the purpose of the funds or harm to shareholder interests [3] - The postponement of investment projects does not involve related transactions and complies with relevant laws and regulations [3]

Core Viewpoint - The company has decided to postpone the expected completion dates for certain fundraising projects due to the current market conditions and industry downturn, while maintaining the original investment purposes and scales [3][4][5]. Fundraising Overview - The company raised a total of RMB 43,177.50 million through the issuance of 30.3 million shares at a price of RMB 14.25 per share, with a net amount of RMB 39,297.76 million after deducting issuance costs [1]. - As of June 30, 2025, the company has allocated funds to various projects, including a technical transformation project for producing 6,000 tons of dimethylpentyl and a high-purity bauxite project [2]. Project Postponement Details - The expected completion date for the 6,000-ton dimethylpentyl technical transformation project has been postponed from September 2025 to September 2026 due to factors such as the pesticide industry's downturn and macroeconomic fluctuations [3][4]. - The decision aims to avoid risks associated with releasing production capacity during an industry low point, ensuring the safety and efficiency of the use of raised funds [3][4]. Impact of Postponement - The postponement does not involve changes to the project implementation entities, investment methods, or total investment amounts, and is not expected to adversely affect the company's normal operations [4][5]. - The board and supervisory committee have both approved the postponement, affirming that it aligns with the company's long-term development strategy and does not harm shareholder interests [5][6]. Regulatory Compliance - The postponement has been reviewed and approved by the board and supervisory committee, and is in compliance with relevant regulations and guidelines regarding the management of raised funds [6].

根据《深圳证券交易所上市公司自律监管指引第2号—创业板上市公司规范运作》 《深圳证券交易所创业板上市公司自律监管指南第1号—业务办理》《企业会计准则》以 及公司关于会计政策的相关规定，绍兴贝斯美化工股份有限公司（以下简称"公司 "） 为真实、准确、客观反映公司的财务状况和经营成果，根据《企业会计准则》相关规定， 本着谨慎性原则，对合并财务报表范围内的各项需要计提减值的资产进行了评估和分析， 对预计可能发生减值损失的相关资产计提减值准备。根据《深圳证券交易所上市公司自 律监管指引第2号—创业板上市公司规范运作》等法律法规的规定，本次计提减值准备无 需提交董事会或股东大会审议，现将具体情况公告如下： 一、本次计提减值准备的情况 （一）本次计提减值准备的原因 证券代码：300796 证券简称：贝斯美 公告编号：2025-064 绍兴贝斯美化工股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或者重大遗漏。 （三）计提资产减值准备的具体说明 根据《企业会计准则第22号金融工具确认和计量》 以及公司会计政策，公 司应收款项、其他应收款以预期信用损失为基础确认信用减值损失， ...

Group 1 - The report details the non-operating fund occupation and related transactions of Shaoxing Baisimei Chemical Co., Ltd. for the first half of 2025, including amounts and reasons for fund occupation [1] - The total non-operating fund occupation at the end of June 2025 amounts to 323,363,046.32 yuan, with significant contributions from related parties [1] - The company has recorded a total of 267,369,206.32 yuan in receivables from its subsidiary Tongling Baisimei Technology Co., Ltd. as of June 2025 [1] Group 2 - The report indicates that the company has engaged in non-operating transactions with its subsidiaries, including a loan of 25,000,000 yuan from Tongling Baisimei Technology Co., Ltd. [1] - Another subsidiary, Ningbo Baisimei New Materials Technology Co., Ltd., has a receivable balance of 18,000,000 yuan as of June 2025, reflecting ongoing financial interactions [1] - The report was approved by the board of directors on August 18, 2025, indicating compliance with corporate governance standards [1]

Core Viewpoint - The company has decided to postpone certain fundraising projects due to market uncertainties and aims to ensure the quality of investment projects while maintaining the safety and efficiency of raised funds [1][5]. Group 1: Fundraising Overview - The company raised a total of RMB 431.775 million by issuing 30.3 million shares at a price of RMB 14.25 per share in November 2019 [1]. - As of June 30, 2025, the company has specific fundraising projects with total investment amounts and cumulative investment amounts detailed in the report [1]. Group 2: Project Adjustments - The company has adjusted the investment total for the "Hydrogen Series and Dimethylpentyl Series Product Technological Transformation Project" and will use surplus funds for new projects, including a "6000 tons Dimethylpentyl Technological Transformation Project" and a "5000 tons High-Purity Bauxite Project" [2]. - The company plans to construct the "5000 tons High-Purity Bauxite Project" in two phases and will use its own funds for the second phase, avoiding the use of raised funds [2]. Group 3: Project Delay Reasons - The postponement of the "6000 tons Dimethylpentyl Technological Transformation Project" from September 2025 to September 2026 is due to the pesticide industry's downturn, macroeconomic fluctuations, and changes in market competition [4]. - The company aims to avoid releasing production capacity during an industry low point to mitigate potential profit declines and will continue to monitor market supply and demand [4]. Group 4: Impact of Delay - The delay does not involve changes to the project implementation entity, method, or total investment amount, and it is not expected to adversely affect the company's normal operations or shareholder interests [5]. - The decision aligns with the company's long-term development strategy and is deemed beneficial for all shareholders [5]. Group 5: Approval Process - The postponement of the fundraising project has been approved by the company's board of directors and supervisory board, complying with relevant regulations and ensuring the interests of all shareholders are protected [5].

（文章来源：证券日报） 证券日报网讯 8月19日晚间，贝斯美发布公告称，公司第四届监事会第六次会议审议通过了《关于公司 2025年半年度报告全文及摘要的议案》等多项议案。 ...

（文章来源：证券日报） 证券日报网讯 8月19日晚间，贝斯美发布公告称，公司第四届董事会第九次会议审议通过了《关于公司 2025年半年度报告全文及摘要的议案》等多项议案。 ...

Core Insights - The announcements highlight various companies' financial performances and strategic decisions, including profit growth, dividend proposals, and investment activities. Financial Performance - Jibite reported a 24.5% year-on-year increase in net profit for the first half of 2025, with revenue growth of 28.49% [4] - Keli Yuan achieved a net profit of 51.22 million yuan, marking a 187.23% increase year-on-year [3] - Yinlong Co. saw a 70.98% increase in net profit, reaching 17.2 million yuan [6] - Xianda Co. experienced a remarkable 2561.58% increase in net profit, totaling 13.6 million yuan [7] - Jinli Yongci reported a 154.81% increase in net profit, amounting to 305 million yuan [11] - Beisimei's net profit grew by 109.7% to 34.71 million yuan [12] - Zhongnan Culture's net profit surged by 524.45% to 60.99 million yuan [13] - Blue Ocean Huaten reported a net profit increase of 159.83%, reaching 41.12 million yuan [15] Dividend Proposals - Jibite plans to distribute a cash dividend of 66 yuan per 10 shares [4] - Huadong Pharmaceutical proposes a cash dividend of 3.5 yuan per 10 shares [8] - Jinli Yongci intends to distribute a cash dividend of 1.8 yuan per 10 shares [11] - Blue Ocean Huaten also plans to distribute a cash dividend of 1.8 yuan per 10 shares [15] Strategic Decisions - Anfu Technology intends to acquire a 31% stake in Anfu Energy for 1.152 billion yuan and raise matching funds [5] - Wanfu Biological decided to terminate a joint investment project with an affiliated company [10] - Dazhi clarified that it has not engaged in "cross-border payment" or related businesses, despite market speculation [2]

（编辑 楚丽君） 证券日报网讯 8月19日晚间，贝斯美发布公告称，公司于2025年8月18日召开了第四届董事会第九次会 议、第四届监事会第六次会议，分别审议通过了《关于公司部分募投项目延期的议案》，同意公司在募 投项目实施主体、实施方式、建设内容、募集资金投资用途及投资规模不发生变更的前提下，对首发部 分募投项目达到预定可使用状态的时间进行调整。 ...

Group 1 - The core viewpoint of the article is that Beishimei reported a revenue of 776 million yuan for the first half of 2025, reflecting a year-on-year growth of 16.57% [1] - The net profit attributable to shareholders of the listed company reached 34.7064 million yuan, showing a significant year-on-year increase of 109.70% [1] - The company announced plans not to distribute cash dividends, issue bonus shares, or increase share capital from reserves [1]